Medical - Care Facilities
Compare Stocks
2 / 10Stock Comparison
AMS vs ARAY
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Devices
AMS vs ARAY — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Medical - Care Facilities | Medical - Devices |
| Market Cap | $12M | $58M |
| Revenue (TTM) | $29M | $429M |
| Net Income (TTM) | $-2M | $-46M |
| Gross Margin | 25.0% | 26.8% |
| Operating Margin | -12.3% | -5.1% |
| Forward P/E | 5.5x | — |
| Total Debt | $23M | $176M |
| Cash & Equiv. | $11M | $57M |
AMS vs ARAY — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| American Shared Hos… (AMS) | 100 | 98.4 | -1.6% |
| Accuray Incorporated (ARAY) | 100 | 23.4 | -76.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: AMS vs ARAY
Each card shows where this stock fits in a portfolio — not just who wins on paper.
AMS carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 32.9%, EPS growth 245.9%, 3Y rev CAGR 17.1%
- -7.7% 10Y total return vs ARAY's -90.3%
- Lower volatility, beta -0.02, Low D/E 77.4%, current ratio 2.52x
In this particular matchup, ARAY is outpaced on most metrics by others in the set.
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 32.9% revenue growth vs ARAY's 2.7% | |
| Quality / Margins | -7.6% margin vs ARAY's -10.8% | |
| Stability / Safety | Lower D/E ratio (77.4% vs 217.3%) | |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | -34.7% vs ARAY's -62.1% | |
| Efficiency (ROA) | -3.8% ROA vs ARAY's -10.1%, ROIC -5.8% vs 3.0% |
AMS vs ARAY — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
AMS vs ARAY — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
Evenly matched — AMS and ARAY each lead in 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ARAY is the larger business by revenue, generating $429M annually — 14.6x AMS's $29M. Profitability is closely matched — net margins range from -7.6% (AMS) to -10.8% (ARAY). On growth, AMS holds the edge at +2.5% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $29M | $429M |
| EBITDAEarnings before interest/tax | $2M | -$15M |
| Net IncomeAfter-tax profit | -$2M | -$46M |
| Free Cash FlowCash after capex | -$10M | -$28M |
| Gross MarginGross profit ÷ Revenue | +25.0% | +26.8% |
| Operating MarginEBIT ÷ Revenue | -12.3% | -5.1% |
| Net MarginNet income ÷ Revenue | -7.6% | -10.8% |
| FCF MarginFCF ÷ Revenue | -34.7% | -6.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | +2.5% | -7.4% |
| EPS Growth (YoY)Latest quarter vs prior year | -56.7% | -6.1% |
Valuation Metrics
Evenly matched — AMS and ARAY each lead in 2 of 4 comparable metrics.
Valuation Metrics
On an enterprise value basis, AMS's 7.1x EV/EBITDA is more attractive than ARAY's 12.7x.
| Metric | ||
|---|---|---|
| Market CapShares × price | $12M | $58M |
| Enterprise ValueMkt cap + debt − cash | $24M | $177M |
| Trailing P/EPrice ÷ TTM EPS | 5.48x | -31.75x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | 0.83x | — |
| EV / EBITDAEnterprise value multiple | 7.12x | 12.68x |
| Price / SalesMarket cap ÷ Revenue | 0.42x | 0.13x |
| Price / BookPrice ÷ Book value/share | 0.40x | 0.62x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
AMS leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
AMS delivers a -7.9% return on equity — every $100 of shareholder capital generates $-8 in annual profit, vs $-77 for ARAY. AMS carries lower financial leverage with a 0.77x debt-to-equity ratio, signaling a more conservative balance sheet compared to ARAY's 2.17x. On the Piotroski fundamental quality scale (0–9), ARAY scores 6/9 vs AMS's 5/9, reflecting solid financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | -7.9% | -77.5% |
| ROA (TTM)Return on assets | -3.8% | -10.1% |
| ROICReturn on invested capital | -5.8% | +3.0% |
| ROCEReturn on capital employed | -6.4% | +2.8% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 6 |
| Debt / EquityFinancial leverage | 0.77x | 2.17x |
| Net DebtTotal debt minus cash | $12M | $119M |
| Cash & Equiv.Liquid assets | $11M | $57M |
| Total DebtShort + long-term debt | $23M | $176M |
| Interest CoverageEBIT ÷ Interest expense | -1.35x | -1.07x |
Total Returns (Dividends Reinvested)
AMS leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in AMS five years ago would be worth $4,372 today (with dividends reinvested), compared to $1,091 for ARAY. Over the past 12 months, AMS leads with a -34.7% total return vs ARAY's -62.1%. The 3-year compound annual growth rate (CAGR) favors AMS at -13.4% vs ARAY's -48.4% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | -13.8% | -42.1% |
| 1-Year ReturnPast 12 months | -34.7% | -62.1% |
| 3-Year ReturnCumulative with dividends | -35.1% | -86.3% |
| 5-Year ReturnCumulative with dividends | -56.3% | -89.1% |
| 10-Year ReturnCumulative with dividends | -7.7% | -90.3% |
| CAGR (3Y)Annualised 3-year return | -13.4% | -48.4% |
Risk & Volatility
AMS leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
AMS is the less volatile stock with a -0.02 beta — it tends to amplify market swings less than ARAY's 2.42 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. AMS currently trades 58.2% from its 52-week high vs ARAY's 23.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | -0.02x | 2.42x |
| 52-Week HighHighest price in past year | $3.11 | $2.10 |
| 52-Week LowLowest price in past year | $1.25 | $0.33 |
| % of 52W HighCurrent price vs 52-week peak | +58.2% | +23.4% |
| RSI (14)Momentum oscillator 0–100 | 61.3 | 53.3 |
| Avg Volume (50D)Average daily shares traded | 126K | 1.3M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 0 | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
AMS leads in 3 of 6 categories — strongest in Profitability & Efficiency and Total Returns. 2 categories are tied.
AMS vs ARAY: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is AMS or ARAY a better buy right now?
For growth investors, American Shared Hospital Services (AMS) is the stronger pick with 32.
9% revenue growth year-over-year, versus 2. 7% for Accuray Incorporated (ARAY). American Shared Hospital Services (AMS) offers the better valuation at 5. 5x trailing P/E, making it the more compelling value choice. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — AMS or ARAY?
Over the past 5 years, American Shared Hospital Services (AMS) delivered a total return of -56.
3%, compared to -89. 1% for Accuray Incorporated (ARAY). Over 10 years, the gap is even starker: AMS returned -7. 7% versus ARAY's -90. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — AMS or ARAY?
By beta (market sensitivity over 5 years), American Shared Hospital Services (AMS) is the lower-risk stock at -0.
02β versus Accuray Incorporated's 2. 42β — meaning ARAY is approximately -15516% more volatile than AMS relative to the S&P 500. On balance sheet safety, American Shared Hospital Services (AMS) carries a lower debt/equity ratio of 77% versus 2% for Accuray Incorporated — giving it more financial flexibility in a downturn.
04Which is growing faster — AMS or ARAY?
By revenue growth (latest reported year), American Shared Hospital Services (AMS) is pulling ahead at 32.
9% versus 2. 7% for Accuray Incorporated (ARAY). On earnings-per-share growth, the picture is similar: American Shared Hospital Services grew EPS 245. 9% year-over-year, compared to 90. 3% for Accuray Incorporated. Over a 3-year CAGR, AMS leads at 17. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — AMS or ARAY?
American Shared Hospital Services (AMS) is the more profitable company, earning 7.
7% net margin versus -0. 3% for Accuray Incorporated — meaning it keeps 7. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ARAY leads at 1. 7% versus -9. 9% for AMS. At the gross margin level — before operating expenses — AMS leads at 32. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — AMS or ARAY?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is AMS or ARAY better for a retirement portfolio?
For long-horizon retirement investors, American Shared Hospital Services (AMS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.
02)). Accuray Incorporated (ARAY) carries a higher beta of 2. 42 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (AMS: -7. 7%, ARAY: -90. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between AMS and ARAY?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: AMS is a small-cap high-growth stock; ARAY is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.